<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00925327</url>
  </required_header>
  <id_info>
    <org_study_id>UVX-004</org_study_id>
    <nct_id>NCT00925327</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of the UV-X System for Corneal Collagen Cross-Linking for Compassionate Treatment in Pediatric Patients With Progressive Keratoconus</brief_title>
  <acronym>CXL</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>Peschke Meditrade, GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peschke Meditrade, GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a compassionate treatment protocol for the use of the UV-X system for corneal
      collagen cross-linking (CXL) in eyes with progressive keratoconus in patients who have
      conditions that limit their capacity to comply with the cross-linking treatment procedures
      required by ongoing clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-randomized study. All eyes that qualify for the study will receive the
      cross-linking (CXL) procedure. Corneal collagen cross-linking is performed as a single
      treatment. Depending on the patient's condition, the CXL procedure may be performed under
      sedation or anesthesia. Subjects are followed for 12 months after the procedure to evaluate
      the long term effects of corneal collagen cross-linking.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in keratometry</measure>
    <time_frame>3 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in manifest refraction spherical equivalent</measure>
    <time_frame>3 Month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">7</enrollment>
  <condition>Progressive Keratoconus</condition>
  <arm_group>
    <arm_group_label>Corneal collagen cross-linking with riboflavin and UVA light</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Corneal collagen cross-linking with riboflavin/UVA light</intervention_name>
    <description>Corneal collagen cross-linking with riboflavin/UVA light</description>
    <arm_group_label>Corneal collagen cross-linking with riboflavin and UVA light</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 6 to 18 years

          -  Having a diagnosis of progressive keratoconus

          -  Signed written informed consent

          -  Having a condition that limits the patient's capacity to comply with the cross-linking
             treatment procedures and/or the diagnostic tests and measurements required by the
             ongoing clinical studies

          -  Willingness and ability to comply with schedule for follow-up visits

        Exclusion Criteria:

          -  Corneal pachymetry at the screening exam that is &lt;400 microns at the thinnest point

          -  Previous ocular condition in the eye(s) to be treated that may predispose the eye for
             future complications, for example (herpes simplex, herpes zoster keratitis, recurrent
             erosion syndrome, corneal melt, or corneal dystrophy, etc.)

          -  A history of delayed epithelial healing in the eye(s) to be treated

          -  Pregnancy or lactation during the course of the study

          -  A known sensitivity to study medications
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Erin D. Stahl, MD</last_name>
    <phone>816-234-3046</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Children's Mercy Hospitals and Clinics</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>65108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Erin D. Stahl, MD</last_name>
      <phone>816-234-3046</phone>
    </contact>
    <investigator>
      <last_name>Scott E. Olitsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Erin D. Stahl, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 19, 2009</study_first_submitted>
  <study_first_submitted_qc>June 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2009</study_first_posted>
  <last_update_submitted>June 19, 2009</last_update_submitted>
  <last_update_submitted_qc>June 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2009</last_update_posted>
  <responsible_party>
    <name_title>Rudi Peschke</name_title>
    <organization>Peschke Meditrade GmbH</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Riboflavin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

